Monday November 23 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Gentiva Health Services, Inc.

Thumbshot of's website
http://www.gentiva.com

Gentiva Health Services, Melville New York, United States of America.

Gentiva Health Services, Inc. is the nation's largest provider of comprehensive home health and related services. Gentiva serves patients through more than 500 direct service delivery units within
Gentiva Health Services - Company Profile



Gentiva(R) Health Services Reports Third Quarter 2009 Results

Thursday 29th of October 2009 7:00

    --  Net revenues of $295.6 million for the quarter ended September 27, 2009
        compared to $345.2 million, which included net revenues of $75.5 million
        from its CareCentrix business unit, for the quarter ended September 28,
        2008. Excluding prior year's third quarter net revenues from
        CareCentrix, Gentiva's net revenues grew over $25 million, or 9% in the
        2009 third quarter. The Company sold a majority ownership interest in
        CareCentrix to Water Street Healthcare Partners on September 25, 2008.

    --  Net income of $15.4 million, or $0.52 per diluted share compared to net
        income of $120.9 million or $4.07 per diluted share in the 2008 third
        quarter. Third quarter 2008 results included a non-recurring gain of
        $107.9 million or $3.67 per diluted share relating to the sale of a
        majority ownership interest in CareCentrix.

    --  Adjusted net income for the 2009 third quarter was $15.9 million, up 27%
        compared with the prior year period. On a diluted earnings per share
        basis, adjusted net income in the 2009 third quarter was $0.54 per
        diluted share compared with $0.42 per diluted share in the corresponding
        period of 2008.  Adjusted net income for both third quarter periods
        excludes special charges of $0.02 per diluted share relating to
        restructuring and merger and acquisition activities. In addition,
        adjusted 2008 third quarter results exclude a non-recurring gain
        relating to the sale of a majority ownership interest in CareCentrix.

    --  Earnings before interest, taxes, depreciation and amortization (EBITDA)
        increased 8% to $31.0 million in the third quarter of 2009. EBITDA as a
        percentage of net revenues improved to 10.5% in the third quarter of
        2009 versus 8.3% in the prior-year period. EBITDA included restructuring
        and integration costs of $0.9 million in the third quarter of 2009 as
        compared to $1.4 million for the prior year period.

"Gentiva continues to execute well on its business strategy and we are well on track to achieve our full year 2009 financial outlook, with expectations toward the higher end of the earnings range," said Gentiva CEO Tony Strange. "Growth trends in both our Home Health and Hospice business units remain solid as we intensify our focus on serving the needs of the nation's growing high-acuity senior population. We are delivering on the key initiatives that will grow our company, including increasing the penetration of our specialty care programs, recruiting and retaining the best caregivers in the business, and operating efficiently, with a strong balance sheet."

Gentiva reported these segment highlights for the quarter:

    --  Home Health revenue growth of 9% to $261.4 million and operating
        contribution growth of 7% to $41.4 million.

    --  Revenues in the All Other segment - which includes hospice, respiratory
        therapy and home medical equipment, infusion therapy and consulting -
        increased 11% to $34.6 million, while operating contribution increased
        70% to $5.0 million compared to the prior-year period.

Gentiva reported these highlights for the nine months ended September 27, 2009:

    --  Net revenues of $882.6 million versus $1.01 billion in the prior year
        period.  Net revenues in the 2008 period included approximately $232.7
        million relating to CareCentrix.  Excluding the revenue contribution
        from CareCentrix, Gentiva's net revenues grew about $103 million, or
        13%, in the nine-month period ended September 27, 2009.

    --  Net income of $50.5 million, or $1.70 per diluted share which included
        (i) a non-recurring pre-tax net gain of $5.7 million or $0.19 per
        diluted share resulting from the 2009 first quarter sale of certain
        branch offices that specialized primarily in pediatric home health care
        services and (ii) special pre-tax charges of $2.4 million or $0.05 per
        diluted share relating to restructuring and merger and acquisition
        costs. These results compared to net income of $140.6 million or $4.80
        per diluted share in the 2008 period which included a net gain of $3.72
        per diluted share from the sale of  CareCentrix and special pre-tax
        charges of $2.1 million or $0.04 per diluted share relating to
        restructuring and merger and acquisition costs.

    --  Adjusted net income was $46.3 million, up 41% compared with the prior
        year period. On a diluted earnings per share basis, adjusted net income
        in the 2009 period was $1.56 compared with $1.12 in the corresponding
        period of 2008. Adjusted net income excludes non-recurring transaction
        gains and special charges relating to restructuring and merger and
        acquisition activities in both periods.

    --  EBITDA increased 13% to $94.7 million versus $84.1 million in the
        prior-year period.

    --  Operating cash flow was $76.5 million in the 2009 period compared to
        $51.1 million in the comparable 2008 period.

At September 27, 2009, the Company reported cash and cash equivalents of $120.3 million and long-term debt of $237.0 million.

Full-Year 2009 Outlook

Gentiva announced that it is reaffirming its revenue and earnings outlook for fiscal 2009. Gentiva anticipates full-year 2009 net revenues will range between $1.19 billion to $1.21 billion. On a diluted earnings per share basis, adjusted net income is expected to be in a range between $2.04 and $2.10 per diluted share. Gentiva's 2009 outlook represents an increase in net revenues of 12% to 14% and an increase in adjusted net income per diluted share of 45% to 50% when compared with 2008 pro forma financial results, which reflect the Company's performance as if the CareCentrix divestiture had occurred at the beginning of fiscal 2008. The 2009 outlook excludes special charges relating to restructuring and merger and acquisition costs which are expected to range between $3 million and $4 million for the year and non-recurring charges and credits. The outlook includes the impact of recently announced acquisitions and also reflects 53 weeks of activity in fiscal 2009.

Non-GAAP Financial Measures

The information provided in this press release includes certain non-GAAP financial measures as defined under Securities and Exchange Commission (SEC) rules. In accordance with SEC rules, the Company has provided, in the supplemental information and the footnotes to the tables, a reconciliation of those measures to the most directly comparable GAAP measures.

Conference Call and Web Cast Details

The Company will comment further on its third quarter 2009 results during its conference call and live web cast to be held Thursday, October 29, 2009 at 10:00 a.m. Eastern Time. To participate in the call from the United States, Canada or an international location, dial (973) 935-2408 and reference call #35210278. The web cast is an audio-only, one-way event. Web cast listeners who wish to ask questions must participate in the conference call. Log onto http://investors.gentiva.com/events.cfm to hear the web cast. A replay of the call will be available on October 29, beginning at approximately 1 p.m. ET, and will remain available continuously through November 5. To listen to a replay of the call from the United States, Canada or international locations, dial (800) 642-1687 or (706) 645-9291 and enter the following PIN at the prompt: 35210278. Visit http://investors.gentiva.com/events.cfm to access the web cast archive. This press release is accessible at http://investors.gentiva.com/releases.cfm and a transcript of the conference call is expected to be available on the site within 48 hours after the call.

About Gentiva Health Services, Inc.

Gentiva Health Services, Inc. is a leading provider of comprehensive home health services, delivering innovative, high quality care to patients across the United States. Gentiva is a single source for skilled nursing; physical, occupational, speech and neurorehabilitation services; hospice services; social work; nutrition; disease management education; help with daily living activities; respiratory therapy and home medical equipment; infusion therapy services; and other therapies and services. For more information, visit Gentiva's web site, http://www.gentiva.com, and its investor relations section at http://investors.gentiva.com. GTIV-E

(unaudited tables and notes follow)




              Gentiva Health Services, Inc. and Subsidiaries
       Condensed Consolidated Financial Statements and Supplemental
                                Information
                                (Unaudited)

        (in 000's, except
         per share data)             3rd Quarter          Nine Months
                                     -----------          -----------
                                    2009      2008      2009        2008
                                    ----      ----      ----        ----
    Statements of Income
    --------------------
        Net revenues              $295,592  $345,243  $882,612  $1,011,089
        Cost of services
         and goods sold            143,490   194,263   425,474     572,106
                                  ------------------  --------------------
        Gross profit               152,102   150,980   457,138     438,983
        Selling, general
         and administrative
         expenses                 (126,624) (127,909) (379,165)   (371,358)
        Gain on sale of
         assets, net                   -     107,872     5,747     107,872
        Interest income                687       338     2,305       1,278
        Interest expense
         and other                  (1,985)   (4,191)   (7,865)    (15,876)
                                  ------------------  --------------------
        Income before
         income taxes               24,180   127,090    78,160     160,899
        Income tax expense           9,013     6,218    28,417      20,280
                                  ------------------  --------------------
        Income before equity
         in net earnings of
         affiliate                  15,167   120,872    49,743     140,619
        Equity in net earnings
         of affiliate                  238        20       779          20
                                  ------------------  --------------------
        Net income                 $15,405  $120,892   $50,522    $140,639
                                  ==================  ====================

      Earnings per Share
      ------------------
        Net income:
           Basic                     $0.53     $4.21     $1.74       $4.94
                                  ==================  ====================
           Diluted                   $0.52     $4.07     $1.70       $4.80
                                  ==================  ====================

        Average shares
         outstanding:
           Basic                    29,154    28,687    29,019      28,489
                                  ==================  ====================
           Diluted                  29,800    29,718    29,648      29,320
                                  ==================  ====================




    Condensed Balance Sheets
    ------------------------
      ASSETS                                        Sept 27, 2009 Dec 28, 2008
      ------                                        ------------- ------------
        Cash and cash equivalents                        $120,298      $69,201
        Short-term investments (A)                          5,000          -
        Accounts receivable, net (B)                      175,728      177,201
        Deferred tax assets                                12,434       11,933
        Prepaid expenses and other current assets          16,487       13,141
                                                    --------------------------
             Total current assets                         329,947      271,476

        Long-term investments (A)                             -         11,050
        Note receivable                                    25,000       25,000
        Investment in affiliate                            24,043       23,264
        Fixed assets, net                                  69,100       63,815
        Intangible assets, net                            253,836      250,432
        Goodwill                                          311,135      308,213
        Other assets                                       23,876       20,247
                                                    --------------------------
            Total assets                               $1,036,937     $973,497
                                                    ==========================

      LIABILITIES AND SHAREHOLDERS' EQUITY
      ------------------------------------
        Accounts payable                                   $7,982       $8,027
        Payroll and related taxes                          24,734       17,869
        Deferred revenue                                   39,893       32,976
        Medicare liabilities                                6,493        6,680
        Obligations under insurance programs               38,530       39,628
        Other accrued expenses                             34,409       40,895
                                                    --------------------------
             Total current liabilities                    152,041      146,075

        Long-term debt                                    237,000      251,000
        Deferred tax liabilities, net                      70,559       64,262
        Other liabilities                                  20,998       17,189
        Shareholders' equity                              556,339      494,971
                                                    --------------------------
             Total liabilities and
              shareholders' equity                     $1,036,937     $973,497
                                                    ==========================

        Common shares outstanding                          29,236       28,864
                                                    ==========================

    (A) Short-term and long-term investments consisted of auction rate
        securities with underlying guarantees carrying a AAA rating.  At
        September 27, 2009, short-term investments were presented at cost as
        the Company settled its remaining ARS at par in early October 2009.
        At December 28, 2008, long-term investments were presented net of a
        valuation allowance of approximately $1.9 million.
    (B) Accounts receivable, net, included an allowance for doubtful accounts
        of $7.3 million and $8.2 million at September 27, 2009 and December
        28, 2008, respectively.



        (in 000's)
                                                            Nine Months
                                                            -----------
    Condensed Statements of Cash Flows                     2009      2008
    ----------------------------------                     ----      ----
      OPERATING ACTIVITIES:
      Net income                                         $50,522  $140,639
      Adjustments to reconcile net income to net cash
      provided by operating activities:
        Depreciation and amortization                     16,705    16,494
        Amortization of debt issuance costs                  952     1,474
        Provision for doubtful accounts                    6,307     9,536
        Equity-based compensation expense                  4,140     4,711
        Windfall tax benefits associated with
         equity-based compensation                          (743)   (2,087)
        Impairment loss on auction rate securities         1,000       -
        Gain on sale of assets, net                       (5,747) (107,872)
        Equity in net earnings of affiliate                 (779)      (20)
        Deferred income taxes                              5,015    11,868
      Changes in assets and liabilities, net of
       effects from acquisitions and dispositions:
        Accounts receivable                               (4,441)  (28,666)
        Prepaid expenses and other current assets         (3,895)   (2,204)
        Current liabilities                                6,617     6,387
      Other, net                                             813       836
                                                        ------------------
      Net cash provided by operating activities           76,466    51,096
                                                        ------------------

      INVESTING ACTIVITIES:
      Purchase of fixed assets                           (18,157)  (19,082)
      Proceeds from sale of assets, net of cash
       transferred                                         5,619    81,760
      Acquisition of businesses, net of cash acquired    (10,325)  (60,634)
      Purchases of short-term investments
       available-for-sale                                    -     (28,000)
      Maturities of short-term investments
       available-for-sale                                  7,000    46,250
                                                        ------------------
      Net cash (used in) provided by investing
       activities                                        (15,863)   20,294
                                                        ------------------

      FINANCING ACTIVITIES:
      Proceeds from issuance of common stock               9,228     9,721
      Windfall tax benefits associated with equity-
       based compensation                                    743     2,087
      Borrowings under revolving credit facility             -      24,000
      Home Health Care Affiliates debt repayments            -      (7,420)
      Debt issuance costs                                    -        (557)
      Repayments under the Company's term loan           (14,000)  (73,000)
      Repurchases of common stock                         (4,813)      -
      Repayment of capital lease obligations                (664)     (899)
                                                        ------------------
      Net cash used in financing activities               (9,506)  (46,068)
                                                        ------------------

      Net change in cash and cash equivalents             51,097    25,322
      Cash and cash equivalents at beginning of period    69,201    36,181
                                                        ------------------
      Cash and cash equivalents at end of period        $120,298   $61,503
                                                        ==================

      SUPPLEMENTAL DISCLOSURES OF CASH
       FLOW INFORMATION:

      Interest paid                                       $7,067   $17,945
      Income taxes paid                                  $27,359    $8,363



        (in 000's)

     Supplemental Information        3rd Quarter         Nine Months
    -------------------------        -----------         -----------
                                   2009      2008      2009        2008
                                   ----      ----      ----        ----
    Segment Information (1)
      Net revenues
        Home Health              $261,444  $239,344  $784,770    $693,220
        CareCentrix                   -      75,546       -       232,717
        All Other (3)              34,582    31,265    99,140      87,821
        Intersegment revenues        (434)     (912)   (1,298)     (2,669)
                                 ------------------  --------------------
      Total net revenues (3)     $295,592  $345,243  $882,612  $1,011,089
                                 ==================  ====================

      Operating contribution (4)
        Home Health               $41,380   $38,841  $133,238    $109,466
        CareCentrix (5)               -       5,225       -        18,074
        All Other                   4,963     2,923    12,084       9,046
                                 ------------------  --------------------
      Total operating
       contribution                46,343    46,989   145,322     136,586
      Corporate expenses          (15,305)  (18,177)  (50,644)    (52,467)
      Gain on sale of assets,
       net                            -     107,872     5,747     107,872
      Depreciation and
       amortization                (5,560)   (5,741)  (16,705)    (16,494)
      Interest expense, net (6)    (1,298)   (3,853)   (5,560)    (14,598)
                                 ------------------  --------------------
      Income before
       income taxes               $24,180  $127,090   $78,160    $160,899
                                 ==================  ====================


                                       3rd Quarter        Nine Months
                                       -----------        -----------
                                      2009     2008     2009       2008
                                      ----     ----     ----       ----

      Net Revenues by Major Payer Source:
        Medicare
          Home Health               $189,994 $165,153 $570,204   $471,515
          Other                       21,835   19,407   62,783     52,900
                                    ----------------- -------------------
          Total Medicare             211,829  184,560  632,987    524,415
        Medicaid and local
         government                   23,733   32,482   76,705     97,001
        Commercial Insurance
         and Other:
           Paid at episodic rates     20,653   14,091   55,947     38,639
           Other                      39,377  114,110  116,973    351,034
                                    ----------------- -------------------
           Total commercial
            insurance and other       60,030  128,201  172,920    389,673
                                    ----------------- -------------------
             Total net revenues     $295,592 $345,243 $882,612 $1,011,089
                                    ================= ===================



    A reconciliation of EBITDA to Net income - As Reported amounts
    follows: (2)
                                         3rd Quarter        Nine Months
                                         -----------        -----------
                                        2009      2008     2009      2008
                                        ----      ----     ----      ----

        EBITDA (4)                    $31,038   $28,812  $94,678   $84,119
        Gain on sale of assets, net       -     107,872    5,747   107,872
        Depreciation and
         amortization                  (5,560)   (5,741) (16,705)  (16,494)
        Interest expense, net (6)      (1,298)   (3,853)  (5,560)  (14,598)
                                      -----------------  -----------------
        Income before income taxes     24,180   127,090   78,160   160,899
        Income tax expense (7)         (9,013)   (6,218) (28,417)  (20,280)
                                      -----------------  -----------------
        Income before equity in net
         earnings of affiliate         15,167   120,872   49,743   140,619
        Equity in net earnings of
         affiliate                        238        20      779        20
                                      -----------------  -----------------
        Net income - As Reported      $15,405  $120,892  $50,522  $140,639
                                      =================  =================


    Notes:
    1) The Company's senior management evaluates performance and allocates
       resources based on operating contributions of the operating segments,
       which exclude corporate expenses, depreciation, amortization, and
       interest expense (net), but include revenues and all other costs
       directly attributable to the specific segment.

    2) EBITDA, a non-GAAP financial measure, is defined as income before
       interest expense (net of interest income), income taxes, depreciation
       and amortization.  Management uses EBITDA to evaluate overall
       performance and compare current operating results with other companies
       in the healthcare industry.  EBITDA should not be considered in
       isolation or as a substitute for net income, operating income or cash
       flow statement data determined in accordance with accounting principles
       generally accepted in the United States.  Because EBITDA is not a
       measure of financial performance under accounting principles generally
       accepted in the United States and is susceptible to varying
       calculations, it may not be comparable to similarly titled measures in
       other companies.

    3) Certain reclassifications have been made to the 2008 third quarter and
       first nine months statements of income and supplemental information to
       conform to the current year presentation.  The primary impact of the
       reclassifications was to reduce (i) net revenues in All Other and (ii)
       cost of services and goods sold by approximately $2.3 million and $6.4
       million, in the third quarter and first nine months of 2008,
       respectively, relating to the reimbursement of nursing home room and
       board charges for hospice patients.

    4) Operating contribution and EBITDA for the third quarter and first nine
       months of 2009 included special charges of $0.9 million and $2.4
       million, respectively.  For the third quarter and first nine months of
       2008, operating contribution and EBITDA included special charges of
       $1.4 million and $2.1 million, respectively.  The special charges,
       which included restructuring and integration costs and costs and
       professional fees associated with merger and acquisition activities,
       were reflected as follows for segment reporting (dollars in millions):


                             3rd Quarter     Nine Months
                             -----------     -----------
                             2009    2008    2009    2008
                             ----    ----    ----    ----

        Home Health          $0.9    $0.1    $1.4    $0.3
        Corporate expenses    -       1.3     1.0     1.8
                             ------------    ------------
        Total                $0.9    $1.4    $2.4    $2.1
                             ============    ============


    5) Operating contribution for CareCentrix, in which the Company sold a
       majority ownership interest on September 25, 2008, was comprised of the
       following (dollars in thousands):


                                    3rd Quarter   Nine Months
                                    -----------   -----------
                                   2009    2008  2009    2008
                                   ----    ----  ----    ----

        Gross profit                 $- $13,669    $- $42,539
        Selling, general and
         administrative expenses      -  (8,589)    - (24,850)
        Add: depreciation             -     145     -     385
                                   ------------  ------------
        Operating contribution       $-  $5,225    $- $18,074
                                   ============  ============



    6) Interest expense, net for the first nine months of 2009 included
       impairment losses on auction rate securities of approximately $1.0
       million.

    7) The Company's effective tax rate was 37.3% and 36.4% for the third
       quarter and first nine months of 2009, respectively, and 4.9% and 12.6%
       for the third quarter and first nine months of 2008, respectively.

       During the 2008 periods, the Company recorded a pre-tax gain, net of
       transaction costs, of $107.9 million and an income tax benefit of
       approximately $1.2 million relating to the sale of a majority interest
       in its CareCentrix unit.  The CareCentrix transaction generated a
       capital loss carryforward for federal tax purposes.  During the first
       nine months of 2009, the Company recorded a pre-tax gain, net of
       transaction costs, of $5.7 million relating to the sale of several
       branch offices that specialized primarily in pediatric home health care
       services.  There was no income tax expense relating to the gain on sale
       of assets in 2009 due to the utilization of a capital loss
       carryforward. Excluding the impact of the non-recurring gains, the
       Company's effective tax rate would have been 37.3% and 39.2% for the
       third quarter and first nine months of 2009, respectively, and 38.9%
       and 40.6% for the third quarter and first nine months of 2008,
       respectively.

Forward-Looking Statement

Certain statements contained in this news release, including, without limitation, statements containing the words "believes," "anticipates," "intends," "expects," "assumes," "trends" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon the Company's current plans, expectations and projections about future events. However, such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These factors include, among others, the following: economic and business conditions, including the ability to access capital markets; demographic changes; changes in, or failure to comply with, existing governmental regulations; legislative proposals for healthcare reform; changes in Medicare and Medicaid reimbursement levels; effects of competition in the markets in which the Company operates; liability and other claims asserted against the Company; ability to attract and retain qualified personnel; availability and terms of capital; loss of significant contracts or reduction in revenues associated with major payer sources; ability of customers to pay for services; business disruption due to natural disasters or terrorist acts; ability to successfully integrate the operations of acquisitions the Company may make and achieve expected synergies and operational efficiencies within expected time-frames; effect on liquidity of the Company's debt service requirements; and changes in estimates and judgments associated with critical accounting policies and estimates. For a detailed discussion of certain of these and other factors that could cause actual results to differ from those contained in this news release, please refer to the Company's various filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section contained in the Company's annual report on Form 10-K for the year ended December 28, 2008.


    Financial and Investor Contact:
          John R. Potapchuk
          631-501-7035
          john.potapchuk@gentiva.com
    or    Brandon Ballew
          770-221-6700
          brandon.ballew@gentiva.com

    Media Contact:
          Scott Cianciulli
          Brainerd Communicators
          212-986-6667
          cianciulli@braincomm.com

SOURCE Gentiva Health Services, Inc.


Browse other news from this organisation: Gentiva Health Services, Inc.

Source PR Newswire

PR Newswire Logo
www.prnewswire.co.uk

Browse news from 2009

Download PDF PDF Version

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.